Get started

Slingshotsystem

$RDAR - Massive Weekly Slingshot, 1000x Potential RunnerWeekend scan continues to find the best candidates into this 8 year cycle - OTC:RDAR , wow is all I can say, this has massive potential once it breaks into sub territory with volume. The hype is in the AI buzz and the constant awareness for their product in the media. Raadr Inc. (OTC: RDAR), also known as Telvantis Inc., is a U.S.-based technology company specializing in AI-driven software solutions aimed at combating cyberbullying and online harassment. The company offers tools for real-time monitoring of social media and digital platforms, targeting parents, schools, and law enforcement agencies. If we learned anything about share structures with bloated OS/AS, it won't mean a damn thing once this sling gets going to the upside - remember how HMBL/ENZC/SNPW, had massive floats and still ran from trips to dollars... I got that itchin' feelin' again, taking a starter Monday and will add on momentum into the sling.
OTC:RDARLong
by ilovestocks85
Multiple Ingredients for a Supernova Soup - $SESLet's start with the fact that this small cap hit my scanner at around 73 cents - and triggered a Tier 1 and Tier 2 buy program above $1.00 - The initial buy signal gap took weeks to fill and confirmed this was not a one-off... to top it all off earnings just blew everyone's socks off with almost a 200% revenue surprise, and if that wasn't good enough they announced a $30mm share buyback of common stock at retail - all of this combined with the AI buzz and a weekly slingshot that looks juicier than ever - we have ourselves a good chance at a multi week runner here. Will not be surprised to see a parabolic move between $10 and $20 PPS.
NYSE:SESLong
by ilovestocks85
Weekly Moonshot Setup for $BLEGChecked all the boxes for this upcoming seasonal wave in the OTC. First one to set off my scanner(87% WR) since early 2021 - $BLEG. This is a low floater with under 900mm shares outstanding, transfer agent verified - pink current status (big green check on these two things).. quick snippet from the Dec 2024 report: A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”) Branded Legacy, Inc. is a diversified holdings company with a primary focus on biotechnology and wellness product development. Over the past year, the company has made significant strides in expanding its operations, acquiring new businesses, and enhancing its product offerings. Business Operations: Branded Legacy, Inc. specializes in the extraction, refinement, and synthesis of alkaloids, providing white/private label services, formulation, and co-packing solutions. The company’s main business activities revolve around the commercial development of alkaloid-infused products such as vapes, tinctures, topicals, and gummies. Additionally, Branded Legacy engages in brand development, marketing, and promoting sustainability practices. The company has expanded its portfolio through strategic acquisitions, including Sycamore BioPharma Inc. and MariJ Pharmaceuticals Inc. These acquisitions have significantly bolstered Branded Legacy's capabilities in botanical extractions and drug delivery systems, enhancing their product offerings and market reach. Product Development and Services: Branded Legacy, Inc. operates through its subsidiaries, Royal Biotek and The Alcannabist, which focus on advancing biotechnical research and development. Royal Biotek, in particular, conducts in-house pre-clinical trials to ensure product efficacy and safety, thereby building consumer trust. The company’s state-of-the-art facilities in Melbourne, FL, support the production and distribution of high-quality wellness products. Sycamore BioPharma, recently acquired by Branded Legacy, is renowned for developing plant-based pharmaceuticals and wellness solutions, including gummies, tinctures, compression sleeves, and pain-relieving topical creams. The acquisition of Sycamore BioPharma has brought over $500,000 in inventory of products and raw materials as well as key personnel for advancing clinical trials. Sycamore supports Branded Legacy's mission to deliver high-quality, innovative products. MariJ Pharmaceuticals, another significant acquisition, specializes in the development and distribution of cannabinoid-based products. This acquisition has added substantial value to Branded Legacy’s portfolio, with MariJ Pharmaceuticals valued at close to $2,000,000. The integration of MariJ Pharmaceuticals has enabled Branded Legacy to expand its product lines and leverage MariJ's expertise in cannabinoid extraction and formulation, further strengthening the company’s position in the biotech and wellness markets. Branded Legacy has also secured exclusive extraction partnerships and developed proprietary delivery systems for various health supplements, further solidifying its position in the wellness industry. The company's innovative approach is evident in its diverse product lines, which include not only traditional botanical extracts but also novel formulations aimed at improving bioavailability and therapeutic effectiveness. Growth and Market Strategy: Branded Legacy is committed to sustainable growth through continuous innovation and strategic partnerships. The company's recent moves include acquiring new facilities, enhancing production capabilities, and expanding its market reach. By integrating advanced biotechnology with robust branding and marketing strategies, Branded Legacy aims to set new benchmarks in the wellness and biotech sectors. The company's forward-thinking approach and strategic acquisitions have positioned it as a leader in the industry, with a focus on delivering high-quality, sustainable products that meet the evolving needs of consumers (Sources: Branded Legacy website, Business Insider). For further details and updates on Branded Legacy's operations, please visit their profile on OTC Markets or their official website. B. List any subsidiaries, parent company, or affiliated companies Total Refinement Solutions, LLC (DBA Royal Biotek) The Alcannabist, LLC MaryJ Pharmaceuticals, Inc. Sycamore Biopharma, Inc. (SBP) All Companies are included in this disclosure statement.
OTC:BLEGLong
by ilovestocks85
$BIOL - WEEKLY SLINGSHOT$BIOL - 2021 Second Quarter Operating Highlights (all comparisons are on a year-over-year basis unless specified otherwise): This is now 3 consecutive Q's of growth back to back: Net revenue grew 211% to $9.1 million: Over 70% of U.S. laser sales came from new customers, continuing a positive trend Over 35% of U.S. Waterlase sales came from dental specialists Net revenue was 6% higher than the pre-pandemic revenues during the second quarter of 2019 Laser system sales increased 424% Consumables and other revenue increased 173% U.S. and international revenue increased 167% and 340%, respectively, as more dental practices were operating during the 2021 second quarter compared to the year-ago second quarter due to the COVID-19 pandemic Gross margin was 44%, up 1,200 basis points, due to the higher year-over-year revenue, favorable revenue mix, and higher average selling prices for products sold during the quarter Net loss was $702,000 or $0.00 per share, compared to a net loss of $4.7 million or $0.12 per share a year ago Maintained strong balance sheet, as cash and cash equivalents totaled $37.1 million at quarter-end "Our strong second-quarter performance is due to rising demand for our industry-leading dental lasers as a result of our intensified focus on education and training, the increased safety our lasers provide to dentists and their patients, and the published studies highlighting the improved results our laser provides to treat perio-disease,” commented John Beaver, President, and Chief Executive Officer. “With over 70% of our U.S. laser sales being generated from new customers during the quarter, and over 35% of our U.S. Waterlase sales coming from dental specialists, it’s clear our messaging, marketing, educational, and training efforts are bearing fruit. However, I believe this is only the beginning because our industry-leading dental lasers provide a better standard of care for dental procedures. In addition, they ensure a safer environment for dental practitioners and patients by reducing aerosolization to mitigate the spread of infectious pathogens, such as COVID-19. Dental practitioners experienced significant disruption to their business during the peak pandemic period. However, our lasers limit their exposure, from a health and business perspective, which was another contributing factor to our strong turnaround from one year ago." "Our focus on educating and training dental specialists on the benefits of our lasers is already leading to increased adoption across these large and untapped markets. In fact, this momentum is giving us greater visibility into Q3, and we feel comfortable providing guidance regarding expected significant year-over-year improvement across our key performance metrics, including revenue and gross margin,” concluded Mr. Beaver.
BLong
by ilovestocks85
$DPW - About to Squeeze$DPW - This one is a blast from the past, prior to the r/s when this stock was near 65 cents, it made its first slingshot breakout and went from what I can remember 10x - 15x within a few weeks ( I linked the previous idea from about 3-4 years ago, which worked out beautifully). Now it is doing it again years later at a higher price and a smaller share structure, so the potential here to see 10x to 15x is even more probable with the current market conditions. I wouldn't be surprised to see the targets reached quickly and surpassed.
DLong
by ilovestocks85
1
$GRST - UPDATED ANALYSIS$GRST: AFTER A SUCCESSFUL BREAKOUT FROM THE CUP AND HANDLE FORMATION ABOVE .003/.0042, $GRST REACHED HIGHS NEARING THE PSYCHOLOGICAL LEVEL OF .01, AND LEVELED OFF TO RETEST THE UPTREND AND FOUND SOLID SUPPORT AT THE BREAKOUT LEVELS FROM THE PREVIOUS FORMATION. WE ARE NOW SWINGING BACK TO RETEST THE PENNY LEVEL, AND WHEN BROKEN THIS TIME AROUND WE SHOULD SEE A PARABOLIC MOVE TOWARDS .03, MANY NEW DEVELOPMENTS INCLUDING $GRST GOING CURRENT ON OTC MARKETS, ARIA FACILITY RECEIVING ITS LICENSE AND OPENING ITS DOORS TO PATIENTS. MUCH MORE MARKETING IS COMING FROM THE COMPANY TO PROMOTE THE FACILITY AND BEGIN GENERATING REVENUES.
OTC:GRSTLong
by ilovestocks85
$FHBC - STRONG WEEKLY BUY SIGNAL$FHBC - VERY SIMILAR TO $ENZC WEEKLY PATTERN, THIS ONE HAS MORE JUICE IN MY OPINION, DUE TO THE FACT THAT IT IS CURRENT ON OTC-MARKETS, HAS PRODUCTS IN STORES ALREADY, AND OVERALL A GOOD TRACK RECORD. VERY CHEAP AT THE MOMENT UNDER .002. MOST SUBS WILL RUN TO PENNIES, AND $FHBC HAS A STRONG BASE IN LOW SUBS NOW ON INCREASING VOLUME TO THE UPSIDE, REFER TO THE CHART I DID ON $ENZC (ALREADY UP OVER 1000% FROM ENTRY) AND YOU WILL SEE THE SAME PATTERN EMERGING
OTC:FHBCLong
by ilovestocks85